{
    "nctId": "NCT00387907",
    "briefTitle": "Study of Larotaxel in Combination With Weekly Herceptin\u00ae in Patients With HER2 Positive Metastatic Breast Cancer",
    "officialTitle": "Open Label, Uncontrolled, Study of XRP9881 (Larotaxel) in Combination With Weekly Trastuzumab (Herceptin\u00ae) in Patients With HER2 Positive Metastatic Breast Cancer (MBC)",
    "overallStatus": "COMPLETED",
    "conditions": "Advanced Breast Cancer, Breast Cancer, Metastatic Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 6,
    "primaryOutcomeMeasure": "Tumor response measured",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Diagnosis of breast cancer\n* Evidence that cancer has spread beyond its original location or has come back and cannot be removed by surgery\n* No more than one prior treatment for advanced disease\n* Her2 positive status\n* Adequate liver and kidney function\n* No remaining severe harmful effects to prior treatments\n\nExclusion Criteria:\n\n* Certain heart condition\n* Pregnant Women\n* History of another cancer except some skin cancers and cervical cancer\n* Taking other treatments for your cancer at the time you enter the trial",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}